John G. Gribben
约翰·格里本
MD, DSc, FMedSci
Professor of Experimental Cancer Medicine实验癌症医学教授
👥Biography 个人简介
Professor John Gribben is a globally recognized authority on follicular lymphoma and B-cell malignancies. His research has fundamentally shaped understanding of how the tumor microenvironment regulates follicular lymphoma biology and resistance to anti-CD20 therapy. He led landmark studies characterizing the prognostic importance of immune cell infiltrates in follicular lymphoma and has contributed extensively to defining molecular mechanisms of rituximab resistance. Gribben has chaired multiple international lymphoma trials and is a frequent contributor to ASCO, EHA, and ASH guidelines on indolent lymphomas.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Tumor Microenvironment in Follicular Lymphoma
Pioneered research demonstrating that immune cell composition within the follicular lymphoma microenvironment is a key determinant of clinical outcome, establishing a paradigm for immune-oncology interactions in indolent B-cell lymphomas.
Rituximab Resistance Mechanisms
Characterized molecular mechanisms of acquired resistance to anti-CD20 therapy, including downregulation of CD20 expression and evasion of complement-dependent cytotoxicity, informing next-generation antibody development.
Obinutuzumab Clinical Evidence
Contributed to the evidence base supporting obinutuzumab-based regimens in previously untreated follicular lymphoma, helping establish the superiority of type II anti-CD20 antibodies in specific clinical contexts.
Representative Works 代表性著作
Tumor-infiltrating T cells correlate with improved survival in follicular lymphoma
Blood (2004)
Landmark paper demonstrating that T-cell subsets within the tumor microenvironment predict prognosis in follicular lymphoma, cited over 1,000 times.
Mechanisms of rituximab resistance in B-cell lymphomas
Journal of Clinical Oncology (2012)
Comprehensive review of resistance mechanisms to anti-CD20 therapy informing next-generation antibody design.
Obinutuzumab for the first-line treatment of follicular lymphoma
New England Journal of Medicine (2017)
GALLIUM trial analysis confirming progression-free survival benefit with obinutuzumab versus rituximab in untreated follicular lymphoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 约翰·格里本 的研究动态
Follow John G. Gribben's research updates
留下邮箱，当我们发布与 John G. Gribben（Barts Cancer Institute, Queen Mary University of London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment